PX578

Asset

Activates mitochondrial polymerase POLG to increase mtDNA levels and enhance mitochondrial function.

Stage: Phase 2
Modality: Small molecule
Target: Oxidative phosphorylation; 3
Indications: 0
Trials: 1
Developer

Indications

3

Mitochondrial disorders
Phase 2, pretzeltx.com, 10 Oct 2026
Polg-mediated primary mitochondrial disease
Phase 2, pretzeltx.com, 10 Oct 2026
POLG mitochondrial disease
Phase 1, pretzeltx.com, 7 Oct 2026

In the full profile

Targets and what it contains4
Owner and partners1
Evidence for its targets4
Competitors9
Aging relevance2

Every asset’s record: target, stage, trials and the evidence behind it.